Celiac Disease Treatment Market 2025: USD 769.3M, 11.6% CAGR

The global Celiac Disease Treatment Market Report 2025-2033 is anchored on a 2025 base value of USD 769.3 million. With an 11.6% compound annual growth rate, the market is projected to reach USD 1,851.0 million by 2033. This asymmetry between a stable base and an accelerated forecast reflects the convergence of three structural forces: better diagnostic capture, an expanding pharmaceutical pipeline, and a maturing dietary supplement infrastructure that supports lifelong adherence. The Vitamins & Minerals segment currently contributes the largest share, consistent with the medical reality that newly diagnosed patients need immediate correction of micronutrient deficiencies.

The Celiac Disease Diagnostics Market is an upstream catalyst; expanded serological screening in North America and Europe has increased confirmed diagnoses by roughly 8% annually since 2022. This, in turn, feeds the treatment market because every diagnosed patient is immediately placed on a gluten-free eating plan and, in most cases, a mineral repletion regimen. The Autoimmune Disease Drugs Market is also shaping expectations, as regulators have become more open to gastrointestinal-specific endpoints. Clinical-stage products in the gluten-degrading enzyme class are progressing rapidly, and their commercial entry will loosen the historical reliance on diet alone.

The demand outlook, however, is not evenly distributed. North America remains the largest revenue pool, while Asia-Pacific is the fastest-growing corridor due to rising gluten intake from processed foods and improving hospital infrastructure. In the Vitamins and Minerals Supplements Market, procurement has shifted toward condition-specific formulas, increasing average selling prices by 7% to 12% over the previous three years. The Hospital Pharmacy Market holds the high-touch patient segment, but retail pharmacies are gaining as patients move to self-managed care. This report benchmarks each of these trajectories and identifies the specific pivots required for market share expansion.

The Vitamins & Minerals segment is projected to contribute USD 338.5 million in 2025, representing about 44% of global revenue. The segment’s size is rarely captured in traditional drug pricing models because it spans categories ranging from prescription iron and vitamin D to condition-specific over-the-counter supplements. Our bottom-up analysis included hospital pharmacy purchase orders, retail scanner data, and payer claims for nutrition deficiency treatment in celiac patients. Iron, vitamin D, folic acid, calcium, and zinc account for 80% of the segment’s value.

Vitamins and minerals do not act in isolation. The Gluten Degrading Enzymes Market is forecast to expand at 19.4% CAGR through 2033, and it overlaps with supplements at the point of accidental gluten exposure. Enzymes are often co-dispensed with nutrients, either as supplements or as ingredients in fortified formulations. The symptomatic treatment sub-segment, including anti-inflammatories and antihistamines, has a smaller 2025 share but will gain meaningful share after the first drug approval.

The segment’s share is stable, but operating margins face pressure from raw material volatility. The Pharmaceutical Excipients Market directly influences the stability of vitamin formulations; a shift toward low-gluten-certified excipients has added 5–8% to ingredient costs. Small and mid-size formulators are responding by entering long-term supply agreements with excipient manufacturers, while larger companies are in-sourcing high-dose iron and vitamin D granulation. The clinical pull-through remains strong: dietary supplementation is part of the standard treatment pathway, creating a steady revenue stream that buffers against pricing cycles. In the broader Gluten-Free Therapeutics Market, segment differentiation is increasingly built on bioavailability, taste-masking, and ingredient transparency.

Drivers

• Diagnostic precision has improved. The Celiac Disease Diagnostics Market is thriving because serology panels now include deamidated gliadin peptide and tissue transglutaminase IgA markers, raising detection sensitivity above 95%. More confirmed cases directly expand the treatment-eligible population, which we estimate grew at 6.9% annually between 2020 and 2025.
• Dietary adherence is poor. Only 34% of celiac patients maintain a strict gluten-free diet for at least five years, according to a validated patient cohort. This behavioral vulnerability is the strongest demand catalyst for gluten-degrading enzymes and for ongoing nutrient repletion, since patients who are non-adherent suffer recurrent deficiencies.
• Payer recognition is rising. Hospital admissions for celiac complications in key European markets increased 12% year-over-year in 2024, prompting insurers to cover disease management programs that include supplements and regular monitoring.

Restraints

• Regulatory classification slows commercialization. In the US, enzymes intended for gluten degradation are often classified as dietary supplements or medical foods rather than drugs, which limits therapeutic claims. The European Medicines Agency, in contrast, applies a borderline product framework that creates inconsistent market access across EU states.
• Clinical trial costs are high. The average Phase III trial for a celiac therapeutic spans 18 months and costs $84 million, yet reimbursement for an ‘accidental exposure’ indication is rarely defined before launch.
• Supply-chain concentration persists. Raw ingredients for specialty vitamins and enzymes—particularly high-grade tapioca maltodextrin, and purified papain—are sourced from a small number of agri-processing regions. Lead times in this category extended from 22 days in 2022 to 31 days in 2025, creating inventory risk for hospital pharmacies.

• Takeda Pharmaceutical Company Limited: Maintains an early-stage pipeline in oral immune tolerance induction and holds commercial nutritional products used in celiac patient care. The company’s strategy centers on disease-modifying approaches with patient-reported outcomes.
• 9 Meters Biopharma, Inc.: Developer of latiglutenase, an orally administered gluten-degrading enzyme candidate designed to break down immunogenic gluten fragments in the stomach. The firm has focused on biomarker-driven enrollment for Phase II/III studies.
• Immunic AG: Its lead investigational agent IMU-856 targets intestinal barrier regulation rather than gluten detoxification, positioning it as a symptomatic treatment for persistent celiac symptoms.
• Dr. Falk Pharma GmbH: Co-developer of ZED1227, a transglutaminase 2 inhibitor, one of the most advanced disease-modifying molecules in the celiac pipeline. European specialty-pharma expertise provides a clear regulatory path.
• Nestlé Health Science: Not a classic drug developer, but its Medical Nutrition arm supplies vitamin and mineral products used widely in celiac management. Distribution through hospital pharmacies and retail chains gives the company a decisive commercial footprint.

Within the broader Celiac Disease Drugs Market, these five companies exemplify the transition from supportive nutrition to targeted therapy. M&A activity is intensifying around enzyme assets, while large pharma companies continue to buy proof-of-concept immunotherapies rather than internalize early-stage risk.

• November 2024: The US FDA issued a dedicated guidance for celiac disease drug development, outlining acceptable endpoints that combine symptom relief with histologic improvement. This removes a long-standing regulatory bottleneck and de-risks future Phase III programs.
• March 2025: A randomized controlled trial for a gluten-degrading enzyme met its primary endpoint, showing a 79% reduction in gluten immunogenic peptides in urine following a 10 g gluten challenge. The manufacturer announced plans for a confirmatory trial.
• June 2025: The European Commission granted orphan drug designation to a transglutaminase 2 inhibitor, providing 10 years of market exclusivity in the EU upon approval. Sponsors indicated a rolling submission start in H1 2026.
• September 2025: A coalition of 12 US-based hospital group purchasing organizations standardized vitamin and mineral supplement contracts for celiac patients, lowering projected procurement costs by 9% and shifting volume to certified gluten-free manufacturers.
• January 2026: Two private biotechnology companies combined their gluten-degrading enzyme and mucosal healing programs to create a more compelling package for late-stage investors.

North America commands the largest regional share, approximately 35% of global revenue, and is expected to grow at a 10.2% CAGR. The US is the anchor, driven by high rates of screening, strong private insurance coverage, and an established hospital pharmacy procurement channel. Regulatory clarity from the FDA has accelerated clinical development, positioning the US as the first launch market for enzyme and TGM2 inhibitor candidates.

Europe trails closely with a 32% share and a 11.1% CAGR. The EU’s gluten-free labeling regulation (EU 828/2014) and ESPGHAN clinical guidelines have streamlined diagnosis and nutritional management. Germany, France, and the UK are the largest contributors. The region is also notable for its high number of academic-initiated clinical trials in celiac disease.

Asia-Pacific is the fastest-growing corridor, with a forecast CAGR of 14.3%. China’s rising processed food consumption, India’s expanding diagnostic infrastructure, and Japan’s centralized screening programs are fueling new treated-patient cohorts. Compared with the Gluten Free Food Market, which is growing at a single-digit pace in the region, medical-grade treatment products face less price sensitivity.

South America and Middle East & Africa represent nearly 10% combined share, with growth between 8.5% and 9.8%. Brazil and South Africa see increasing private laboratory testing, but out-of-pocket costs constrain advanced nutritional products. These regions will remain secondary for commercial launches but are attractive for low-cost vitamin/mineral volume.

Average selling prices vary widely by segment and channel. A one-month vitamin and mineral repletion protocol for celiac patients ranges from $19 in retail pharmacies to $42 in hospital pharmacies when intravenous iron and high-dose vitamin D are included. Gluten-degrading enzymes, positioned as premium adjuncts, carry a 35–55% price premium over standard supplements.

The cost structure of a typical vitamin/mineral product is heavily weighted toward raw materials: active ingredients account for 45% of cost of goods sold, excipients 15%, direct labor 12%, packaging 10%, logistics 12%, and overhead 6%. Protein-based enzyme products have a different cost curve—fermentation and purification raise raw material costs to 60% of COGS. This cost burden limits price discounting in institutional contracts.

Margins are highest in the retail channel, where branded supplements sustain 35–40% gross margin. Hospital pharmacy margins are compressed to 22–25% due to group purchasing pressure. Over the forecast period, inflation in pharmaceutical-grade minerals and low-gluten excipients is expected to exceed 3% annually, pushing rationalization and consolidation across the supply chain.

Venture capital and private equity interest in celiac disease treatments has accelerated markedly. Between 2023 and 2025, more than $420 million was deployed globally into celiac-specific drug and nutritional companies, with 68% directed to enzyme and immune-modulating candidates. The Autoimmune Disease Drugs Market has been a source of strategic acquirers; two mid-sized pharma companies acquired early-stage celiac assets in 2024 to diversify their GI pipelines.

The Hospital Pharmacy Market is also attracting supply-chain investment, as GPOs and distributors build dedicated celiac procurement categories. In the vitamins space, three specialty supplement makers received growth equity rounds to fund gluten-free-certified manufacturing lines. High-growth sub-segments attracting capital include gluten-degrading enzymes, transglutaminase 2 inhibitors, and microbiome-based symptomatic treatments. Strategic acquirers favor assets with clear regulatory pathways and proven biomarker readouts, making celiac programs increasingly attractive to specialty pharmaceutical buyers.

• 1. Treatment
  • 1.1. Vitamins & Minerals
  • 1.2. Gluten Degrading Enzymes
  • 1.3. Symptomatic Treatment (Anti-inflammatory Drugs, Antihistamines, Others)
  • 1.4. Other Treatments
• 2. Distribution Channel
  • 2.1. Hospital Pharmacies
  • 2.2. Retail Pharmacies
  • 2.3. Other Distribution Channels

• 1. North America
  • 1.1. United States
  • 1.2. Canada
  • 1.3. Mexico
• 2. South America
  • 2.1. Brazil
  • 2.2. Argentina
  • 2.3. Rest of South America
• 3. Europe
  • 3.1. United Kingdom
  • 3.2. Germany
  • 3.3. France
  • 3.4. Italy
  • 3.5. Spain
  • 3.6. Russia
  • 3.7. Benelux
  • 3.8. Nordics
  • 3.9. Rest of Europe
• 4. Middle East & Africa
  • 4.1. Turkey
  • 4.2. Israel
  • 4.3. GCC
  • 4.4. North Africa
  • 4.5. South Africa
  • 4.6. Rest of Middle East & Africa
• 5. Asia Pacific
  • 5.1. China
  • 5.2. India
  • 5.3. Japan
  • 5.4. South Korea
  • 5.5. ASEAN
  • 5.6. Oceania
  • 5.7. Rest of Asia Pacific